A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach
In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder.
You may also be interested in...
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.